1187-59-3

Basic information

• Product Name: N-METHYLACRYLAMIDE
• Synonyms: 2-Propenamide,N-methyl-;n-methyl-2-propenamid;N-methyl-2-Propenamide;n-methyl-acrylamid;N-METHYLACRYLAMIDE;N-methylprop-2-enamide
• CAS NO: 1187-59-3
• Molecular Formula: C₄H₇NO
• Molecular Weight: 85.1
• EINECS: 214-700-0
• Product Categories: monomer
• Mol File: 1187-59-3.mol
• Article Data: 12

Chemical Properties

• Melting Point: 102-106 °C
• Boiling Point: 156.6°C (rough estimate)
• Flash Point: 103.6 °C
• Appearance: /
• Density: 1.0408 (rough estimate)
• Vapor Pressure: 0.222mmHg at 25°C
• Refractive Index: 1.4340 (estimate)
• Storage Temp.: 2-8°C
• PKA: 15.12±0.46(Predicted)
• CAS DataBase Reference: N-METHYLACRYLAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-METHYLACRYLAMIDE(1187-59-3)
• EPA Substance Registry System: N-METHYLACRYLAMIDE(1187-59-3)

Safety Data

• Statements: 20/21/22-36/37/38
• Safety Statements: 23-26-36/37/39
• RIDADR: 2810
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 1187-59-3(Hazardous Substances Data)

Usage

Safety Profile

Moderately toxic by ingestion. Experimental reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx.

InChI:InChI=1/C4H7NO/c1-3-4(6)5-2/h3H,1H2,2H3,(H,5,6)

Upstream product

• 6830-81-5 3-hydroxyl-N-methylpropanamide 
• 57-57-8 β-Propiolactone 
• 74-89-5 methylamine 
• 5450-85-1 2-acetoxy-propionic acid methylamide 
• 814-68-6 acryloyl chloride 
• 140-88-5 ethyl acrylate 
• 24685-31-2 methyl N-allyl-N-acrylamide 
• 74-86-2 acetylene 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 38188-92-0 β-Methoxypropionsaeure-monomethylamid 
• 50836-82-3 N-methylamide of β-methylaminopropionic acid 
• 39198-51-1 N-methyl-endo-bicyclo<2.2.1>hept-5-ene-2-carboxamide 
• 593-51-1 methylamine hydrochloride 
• 2682-32-8 N-methyl-2-propynamide 

Downstream Products

• 757-87-9 Dithiophosphoric acid O,O'-dimethyl ester S-[2-(1-methylcarbamoyl-ethylsulfanyl)-ethyl] ester 
• 2680-03-7 N,N-Dimethylacrylamide 
• 207804-83-9 N-acryloyl-N-methyl-N'-p-tolylsulfonylurea 
• 1001345-72-7 N-methyl-3-(propan-2-ylamino)propanamide 
• 1001346-14-0 3-(butan-2-ylamino)-N-methyl-propanamide 
• 1001346-35-5 3-(2-methoxyethylamino)-N-methyl-propanamide 
• 1258852-55-9 3-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3,4-thiadiazol-2-yl)-3,4-dihydro-2(1H)-isoquinolinyl]-N-methylpropanamide 
• 1342826-49-6 3-(4-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)-N-methylpropanamide 
• 1307612-93-6 C₁₃H₂₀N₂O₃ 
• 297734-22-6 C₁₀H₂₀N₂O 
• 50836-82-3 N-methylamide of β-methylaminopropionic acid 

Relevant articles and documents

-

-

Catalytic, transition-metal-free semireduction of propiolamide derivatives: Scope and mechanistic investigation

We report a transition-metal-free trans-selective semireduction of alkynes with pinacolborane and catalytic potassium tert-butoxide. A variety of 3-substituted primary and secondary propiolamides, including an analog of FK866, a potent nicotinamide mononucleotide adenyltransferase (NMNAT) inhibitor, are reduced to the corresponding (E)-3-substituted acrylamide derivatives in up to 99% yield with >99:1 E/Z selectivity. Mechanistic studies suggest that an activated Lewis acid-base complex transfers a hydride to the α-carbon followed by rapid protonation in a trans fashion.

BIARYL AMIDES WITH MODIFIED SUGAR GROUPS FOR TREATMENT OF DISEASES ASSOCIATED WITH HEAT SHOCK PROTEIN PATHWAY

Provided are biaryl amides and coumarin-based compounds with modified sugar groups for treatment of diseases associated with heat shock protein pathway. The compounds having the following formulas, wherein variables are as defined herein. Formulae (I), (II), (III), (IV), and (V), Pharmaceutical compositions of the compounds are also provided. These biaryl amides and coumarin-based derivatives with modified sugar groups are useful for treatment and prevention of diseases and disorders, including neurological disorders, such as neurodegenerative diseases and nerve damaging disorders, for example, diabetic peripheral neuropathy.